Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Docusate Sodium 250 mg

cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Ongoing Packaging defect Safecor Health, LLC NDC 48433-101-01 D-0060-2025
Class II · Moderate risk

Calcium Carbonate Chewable 500 mg

cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Ongoing Packaging defect Safecor Health, LLC NDC 48433-106-01 D-0059-2025
Class II · Moderate risk

Aspirin Chewable tablet 81 mg

cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Ongoing Packaging defect Safecor Health, LLC NDC 48433-129-01 D-0058-2025
Class II · Moderate risk

Vitamin B1

cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Ongoing Packaging defect Safecor Health, LLC NDC 48433-108-01 D-0057-2025
Class II · Moderate risk

Vitamin D3

cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Ongoing Packaging defect Safecor Health, LLC NDC 48433-104-01 D-0056-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-832-30 D-0078-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-831-30 D-0077-2025
Class II · Moderate risk

Trinity Gold Nutrition

Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared acetaminophen, diclofenac and phenylbutazone.

Ongoing Chemical / undeclared Trinity Gold Nutrition D-0042-2025
Class III · Low risk

Hydralazine HCl Tablets

Failed Impurities/Degradation Specifications; during routine stability testing for impurities.

Terminated Impurity / degradation The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6441-61 D-0045-2025
Class I · High risk

ZapMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0086-2025
Class I · High risk

ZoomMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0085-2025
Class I · High risk

PeakMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0084-2025
Class I · High risk

VitalityXtra Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0083-2025

Recalls by year